Longevity companies make key appointments

Longevity companies make key appointments

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Two longevity companies have bolstered their teams with the announcement of new board and executive appointments. Clinical stage longevity biotech Longeveron (NASDAQ: LGVN) announced the election of three new members to its board of directors, while cellular health supplements company MitoQ has appointed Dr Siobhan Mitchell as Chief Science and Technology Officer.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

LTUI: 2251

Longeveron

Longevity level(s):

  • Level 6: Aging disease prevention therapeutics
    Therapeutic interventions that control aging drivers to prevent aging diseases from occurring, like the current wave of GLP-1 agonists that prevent type 2 diabetes through metabolic interventions that also are proving effective in mitigating cardiovascular and neurological diseases.
  • Level 7: Targeted aging disease reversal
    Therapeutic interventions that stop or reverse age-related damage in specific organs (organ specific / tissue specific / localized reversal) or for age-related diseases including technologies like partial cellular reprogramming.

Overview

Longeveron is a clinical-stage regenerative medicine biotechnology company headquartered in Miami, Florida, developing culture-expanded mesenchymal stem cell therapies to address life-threatening and chronic aging-related conditions. The company's lead investigational product, laromestrocel (Lomecel-B™), is derived from bone marrow-sourced mesenchymal stem cells from young healthy adult donors and is designed to modulate immune function and promote tissue repair. Longeveron is advancing multiple clinical programs targeting hypoplastic left heart syndrome, Alzheimer's disease, aging-related frailty, and other age-associated pathologies, with the goal of improving healthspan and extending longevity through cellular regeneration.

Access all data points on DLT:

  • Financial Data
  • Patents
  • Technology
  • Management
  • Advisory Board
  • News
  • Classifications
  • Similar Companies
Expand

LT Staff

Longevity.Technology's in-house writing staff.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Ferring moves to acquire Gameto in $1.38b deal

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE